
A2A Pharma
Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of
Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE
A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer LEARN MORE